Search Within

Population Sciences Research Program

  1. "Epidemiology and Biostatistics"
  2. "Biostatistics Service"
  3. "Center for Hematologic Malignancies"
Formats
  1. Meeting Abstract (145)
  2. Journal Article (144)
  3. Research Letter (12)
  4. Correspondence (3)
  5. Conference Paper (2)
Groups
  1. Biostatistics Service (306)
  2. Center for Hematologic Malignancies (306)
  3. Epidemiology and Biostatistics (306)
  4. Department of Medicine (281)
  5. Hematologic Malignancies, Division of (271)
  6. Survivorship Research (187)

More Groups

People
  1. Andriy Derkach (110)
  2. Sergio Giralt (71)
  3. Alexander Lesokhin (62)
  4. Malin Hultcrantz (60)
  5. Urvi Shah (57)
  6. Gunjan Shah (55)

More People

Years
  1. 2024 (2)
  2. 2023 (53)
  3. 2022 (45)
  4. 2021 (30)
  5. 2020 (37)
  6. 2019 (18)

More Years

Publications
  1. Blood (85)
  2. Journal of Clinical Oncology (36)
  3. Clinical Lymphoma, Myeloma and Leukemia (18)
  4. Blood Advances (13)
  5. Clinical Cancer Research (11)
  6. Leukemia and Lymphoma (9)

More Publications

Publishers
  1. American Society of Hematology (98)
  2. American Society of Clinical Oncology (37)
  3. Elsevier Inc. (31)
  4. Nature Publishing Group (27)
  5. American Association for Cancer Research (22)
  6. Wiley Blackwell (13)

More Publishers

Results (306)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pre-diagnosis dietary patterns and risk of multiple myeloma in the NIH-AARP diet and health study
    Research Letter

    Castro, F.; Parikh, R.; Eustaquio, J. C.; Derkach, A.; Joseph, J. M.; Lesokhin, A. M.; Usmani, S. Z.; Shah, U. A.
    Leukemia (2024)

    Fulltext@MSK | Save
  • Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups
    Journal Article

    Shah, U. A.; Moshier, E.; Derkach, A.; Huang, Y.; Mailankody, S.; Tan, C. R.; Maclachlan, K.; Hultcrantz, M.; Korde, N.; Hassoun, H.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save
  • Clinical Factors but not somatic mutations predict for survival in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplant: Analysis of the North American myelofibrosis transplant outcome (NAMTO) study
    Meeting Abstract

    Ajufo, H.; Derkach, A.; Rampal, R. K.; Famulare, C.; Nemirovsky, D.; Chervin, J.; Ho, V.; Gupta, V.; Viswabandya, A.; Deeg, H. J.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Impact of symptom benefit and transfusion response on survival in myelofibrosis patients treated with pacritinib: PERSIST-2 landmark survival analysis
    Meeting Abstract

    Ajufo, H.; Bewersdorf, J. P.; Harrison, C. N.; Palandri, F.; Mascarenhas, J.; Palmer, J.; Gerds, A. T.; Kiladjian, J. J.; Buckley, S.; Derkach, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A phase 2 study of minimal residual disease (MRD)-adapted front line venetoclax and obinutuzumab in fit patients with chronic lymphocytic leukemia (CLL): Effect of obinutuzumab on tumor lysis syndrome (TLS) risk and safety of outpatient venetoclax dose escalation
    Meeting Abstract

    Roeker, L. E.; Zelenetz, A. D.; Park, J. H.; Derkach, A.; Geyer, M. B.; Islam, P.; Falchi, L.; Palomba, M. L.; Kumar, A.; Salles, G.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
    Meeting Abstract

    Bewersdorf, J. P.; Derkach, A.; Masarova, L.; Pemmaraju, N.; Stein, E. M.; Mauro, M.; Rampal, R. K.; Bose, P.
    Blood (2023)

    Fulltext@MSK | Save
  • A phase 1b multi-center study of the FLT3 inhibitor gilteritinib in combination with the IDH1 inhibitor ivosidenib or the IDH2 inhibitor enasidenib for patients with relapsed or refractory acute myeloid leukemia who have co-occurring FLT3/IDH1 or FLT3/IDH2 mutations
    Meeting Abstract

    Stein, E. M.; Derkach, A.; Melamed, G.; Block, A.; Kim, J.; Georgieva, G.; Thompson, V.; Levine, R. L.; Intlekofer, A. M.; Abdel-Wahab, O.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Pilot study of longitudinal geriatric assessment and neurocognitive evaluation in CAR T-cell therapy for older patients with relapsed refractory, large B-cell lymphoma
    Meeting Abstract

    Lin, R. J.; Kim, S. J.; Correa, D.; Elko, T. A.; Lobaugh, S.; Baser, R.; Koch, A.; Hanley, D. M.; Palomba, M. L.; Dahi, P. B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) and daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C.; Maclachlan, K. H.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Rajeeve, S.; Patel, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • T-cell exhaustion signature predicts early relapse after autologous stem cell transplant for multiple myeloma: BMT CTN 0702 secondary immune analysis
    Meeting Abstract

    Mehanna, N.; Derkach, A.; Gasmi, B.; Anagnostou, T.; Landau, H.; Lahoud, O. B.; Scordo, M.; Shah, G. L.; Hassoun, H.; Maclachlan, K. H.; more...
    Blood (2023)

    Fulltext@MSK | Save